Relieves discomfort associated with acute, painful musculoskeletal conditions. ANDA 40823, held by Ingenus Pharms LLC. Carisoprodol.
As of Nov 16, 2026, ANDA 40823 (Carisoprodol), held by Ingenus Pharms LLC, was first approved by FDA on Oct 22, 2008, with 2 approved supplements and 0 published complete response letters.
CARISOPRODOL is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Limitation of Use CARISOPRODOL should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration..
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 22, 2008 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Carisoprodol350MG · tablet;oral | Carisoprodol | Rx |
| Apr 24, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 16, 2011 | Supplement 1Labeling | Approved | None posted |
| Oct 22, 2008 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters